button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 0.61 [0.40; 0.93], 1 RCT, I2=0%
unassessable degree of certainty		 0.48 [0.36; 0.64], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 0.68 [0.53; 0.87], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.59 [0.49; 0.72], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
durvalumab alone vs. Standard of Care (SoC) 1 0.96 [0.81; 1.13], 1 RCT, I2=0%
inconclusive result		--

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin 1 0.78 [0.60; 1.02], 1 RCT, I2=0%
inconclusive result		 0.73 [0.56; 0.95], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 0.83 [0.65; 1.06], 1 RCT, I2=0%
inconclusive result		 0.77 [0.63; 0.94], 1 RCT, I2=0%
unassessable degree of certainty		-
cemiplimab vs. Standard of Care (SoC) 1 0.57 [0.42; 0.77], 1 RCT, I2=0%
unassessable degree of certainty		 0.54 [0.43; 0.68], 1 RCT, I2=0%
unassessable degree of certainty		-
durvalumab alone vs. Standard of Care (SoC) 1 0.76 [0.56; 1.03], 1 RCT, I2=0%
inconclusive result		 0.87 [0.59; 1.29], 1 RCT, I2=0%
inconclusive result		-
nivolumab alone vs. Standard of Care (SoC) 2 1.07 [0.86; 1.33], 1 RCT, I2=0%
inconclusive result		 1.17 [0.95; 1.44], 1 RCT, I2=0%
inconclusive result		-
pembrolizumab alone vs. Standard of Care (SoC) 4 0.74 [0.56; 0.97], 2 RCTs, I2=51% conclusive
moderate degree of certainty		 0.74 [0.35; 1.56], 2 RCTs, I2=95%
inconclusive result		-

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 0.80 [0.65; 0.99], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.65 [0.54; 0.78], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 0.76 [0.63; 0.92], 1 RCT, I2=0%
unassessable degree of certainty		 0.61 [0.52; 0.72], 1 RCT, I2=0%
unassessable degree of certainty		-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 0.85 [0.71; 1.02], 1 RCT, I2=0%
inconclusive result		 0.91 [0.78; 1.06], 1 RCT, I2=0%
inconclusive result		-

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.58 [0.49; 0.70], 2 RCTs, I2=21% conclusive
moderate degree of certainty		-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 0.79 [0.64; 0.98], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.64 [0.54; 0.76], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 0.81 [0.64; 1.03], 1 RCT, I2=0%
inconclusive result		 0.60 [0.49; 0.73], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 0.90 [0.42; 1.92], 1 RCT, I2=0%
inconclusive result		 0.53 [0.31; 0.91], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 0.49 [0.38; 0.64], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.52 [0.43; 0.63], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 0.88 [0.73; 1.06], 1 RCT, I2=0%
inconclusive result		 0.71 [0.60; 0.85], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 0.64 [0.49; 0.84], 1 RCT, I2=0% conclusive
unassessable degree of certainty		 0.56 [0.45; 0.70], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons